Virax Biolabs Group Ltd. has announced the successful completion of patient recruitment for its United Kingdom-based, multi-centre clinical study evaluating the ViraxImmune™ assay. The study focuses on detecting T cell dysfunction in Post-Acute Infection Syndromes, including Long COVID, post-treatment Lyme disease, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. The company has also received constructive feedback from the U.S. Food and Drug Administration regarding the regulatory pathway for the ViraxImmune™ T cell assay and plans to begin a U.S.-based clinical study in partnership with Emory University in 2026. Initial read-outs from the ongoing longitudinal study are expected in the second quarter of 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Virax Biolabs Group Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: DA13716) on November 03, 2025, and is solely responsible for the information contained therein.